secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eikon Therapeutics, Inc. (EIKN)
CIK:        0001861123
Form:       8-K
Filed at:   2026-08-13T20:06:11+00:00
Accession:  0001193125-26-349154
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eikon Q2 2026 net loss $88.4M, cash $531.2M; EIK1001 DMC selects dose
---------------------------------------------------------------------

- Net loss $88.4M vs $105.2M prior year; R&D $75.5M (+9%), G&A $17.9M (-56%).
- Cash $531.2M at June 30, 2026; expected to fund operations into H2 2027.
- EIK1001 TeLuRide-006 DMC selected single dosing regimen; TeLuRide-008 first patient dosed.
- Seven abstracts accepted at ESMO 2026; initial EIK1004 and EIK1005 data to be presented.
- Appointed Ma. Fatima Francisco to Board; EIK1006 IND expected by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/0001193125-26-349154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/eikn-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer